Delving into the Latest Updates on BI-706039 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

RIPK2

Mechanism

RIPK2 inhibitors(Serine/threonine-protein kinase RIPK2 inhibitors)

Therapeutic Areas

Immune System DiseasesDigestive System Disorders

Active Indication

Inflammatory Bowel Diseases

Inactive Indication-

Originator Organization

Boehringer Ingelheim GmbH

Active Organization

Boehringer Ingelheim GmbH

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Author: Simpson, Tom ; Zheng, Jie ; Li, Li ; Csordas, David ; Byrne, Fergus R. ; Lukas, Susan ; Jost, Felix ; Ting, Naitee ; Ermann, Joerg ; Klimowicz, Alex P. ; Fine, Jay S. ; King, F. James ; Miller, Craig A. ; Mierz, Diane ; Matmusaev, Mederbek ; Braun, Clemens ; Mayer-Wrangowski, Svenja ; Terenzio, Donna ; Panzenbeck, Mark ; Patnaude, Lori ; Hsiao, Peng ; Chime, Jane ; Mbow, M. Lamine ; Haley, Emma K. ; Fogal, Steve E.

The RIPK2 kinase at the apex of microbiome immunosensing is an attractive target for pharmacological intervention. A low oral dose of a RIPK2 inhibitor leads to significantly improved intestinal inflammation in the murine TRUC model of colitis. A selective and potent inhibitor of the RIPK2 kinase may represent a new class of therapeutics that target microbiome-driven signaling for the treatment of IBD.

100 Deals associated with BI-706039

Login to view more data